Literature DB >> 11062006

Unusual laminin alpha2 processing in myoblasts from a patient with a novel variant of congenital muscular dystrophy.

G Lattanzi1, F Muntoni, P Sabatelli, S Squarzoni, N M Maraldi, V Cenni, M Villanova, M Columbaro, L Merlini, S Marmiroli.   

Abstract

We recently described a novel congenital muscular dystrophy (CMD) syndrome characterized by mental retardation, microcephaly, and partial merosin deficiency on muscle biopsy. Linkage analysis excluded involvement of the known CMD loci. We now report on a study performed on the differentiation of cultured myoblasts from one patient affected by this condition to evaluate the potential to form myotubes and merosin processing in these cells. The differentiation rate was comparable to controls and myotubes were stable in culture. Biochemical analysis showed the expected 80-kDa merosin subunit in myoblasts. However, a shifted 60-kDa protein was detected in myotubes. Matrix-metalloproteinases (MMPs) zymography showed increased gelatinolytic activity, and immunoblotting identified an increased amount of membrane-type 1 matrix-metalloproteinase in pathological myotube preparations. Our results show that these CMD-derived myotubes contain a low molecular weight merosin. They further suggest that an altered regulation of MMPs can be involved in basal lamina damage. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062006     DOI: 10.1006/bbrc.2000.3735

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Ku70 regulates Bax-mediated pathogenesis in laminin-alpha2-deficient human muscle cells and mouse models of congenital muscular dystrophy.

Authors:  Vivek K Vishnudas; Jeffrey Boone Miller
Journal:  Hum Mol Genet       Date:  2009-08-19       Impact factor: 6.150

2.  Genetic overexpression of Serpina3n attenuates muscular dystrophy in mice.

Authors:  Andoria Tjondrokoesoemo; Tobias Schips; Onur Kanisicak; Michelle A Sargent; Jeffery D Molkentin
Journal:  Hum Mol Genet       Date:  2016-01-06       Impact factor: 6.150

3.  The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.

Authors:  Yoram Nevo; Shlomit Aga-Mizrachi; Edva Elmakayes; Nurit Yanay; Keren Ettinger; Moran Elbaz; Zivia Brunschwig; Oshrat Dadush; Galit Elad-Sfadia; Roni Haklai; Yoel Kloog; Joab Chapman; Shimon Reif
Journal:  PLoS One       Date:  2011-03-22       Impact factor: 3.240

4.  Expression of collagen VI α5 and α6 chains in human muscle and in Duchenne muscular dystrophy-related muscle fibrosis.

Authors:  Patrizia Sabatelli; Francesca Gualandi; Sudheer Kumar Gara; Paolo Grumati; Alessandra Zamparelli; Elena Martoni; Camilla Pellegrini; Luciano Merlini; Alessandra Ferlini; Paolo Bonaldo; Nadir Mario Maraldi; Mats Paulsson; Stefano Squarzoni; Raimund Wagener
Journal:  Matrix Biol       Date:  2011-12-30       Impact factor: 11.583

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.